• At the heart of the PD disease process is the misfolding and propagation of the protein α-synuclein1
  • The pathology typical of PD is first seen, within the brain, in the dorsal motor nucleus, and spreads upwards from there2
  • A milestone in understanding came in 2008, when Lewy body-like inclusions were observed in neurons that had been grafted (from foetal tissue) into the brains of patients with PD, 11–16 years after the grafts were performed1  
  • This observation was ground-breaking, because it suggested host-to-graft transmission of PD pathology1

file_download Download in HQ

Related content

image Image Image showing mechanisms for targeting α-synuclein in Parkinson’s disease research
Possible α-synuclein targets for development of therapies for Parkinson’s disease

Overview of three therapeutic strategies targeting alpha-synuclein in the development of disease-modifying treatments for Parkinson’s disease

26.06.2025 Parkinson’s Disease
image Image Image showing potential effects of disease-modifying treatments on Parkinson’s disease progression
Disease modification in Parkinson’s disease

Graphical representation of how various treatment strategies can impact disease progression in Parkinson’s disease, from symptom relief to potential cure

26.06.2025 Parkinson’s Disease
image Image Image showing how COMT inhibitors increase dopamine availability
Catechol-O-methyltransferase (COMT) inhibitors mechanism of action

Illustration of how COMT inhibitors increase dopamine availability in Parkinson’s disease by preventing the breakdown of L-DOPA

26.06.2025 Parkinson’s Disease